Search for Clinical Trial Results

Sponsored By

Hematologic Neoplasms - 25 Studies Found

Status Study
Recruiting Study Name: A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers
Condition: Hematologic Neoplasms
Date: 2015-02-13
Interventions:
  • Drug: CC-90002
  • Drug: Rituximab
Recruiting Study Name: Phase I Trial of BAY1251152 for Advanced Blood Cancers
Condition: Hematologic Neoplasms
Date: 2016-04-18
Interventions: Drug: BAY1251152 Weekly infusion of BAY1251152 in 21-day cycles.
Completed Study Name: Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.
Condition: Hematologic Neoplasms
Date: 2006-10-16
Interventions: Drug: CPX-351 (Cytarabine:Daunorubicin) Liposome Injection
Completed Study Name: Biomarker Research for Personalized Medicine
Condition: Hematologic Neoplasms
Date: 2011-12-06
Completed Study Name: A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.
Condition: Hematologic Neoplasms
Date: 2008-02-18
Interventions: Drug: RO5045337 Multiple ascending doses
Terminated Study Name: A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies
Condition: Haematological Malignancies
Date: 2010-03-02
Interventions:
  • Drug: AS703569

Active, not recruiting Study Name: Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
Condition: Hematologic Neoplasms
Date: 2013-02-26
Interventions: Drug: Panobinostat single agent panobinostat starting with last assigned dose and regimen which patient
Active, not recruiting Study Name: Intra-bone Cord Blood Transplantation in Patients With Haematological Malignancies
Condition:
  • High Risk Haematological Malignancies
  • Advanced Hematologic Neoplasms
    Date: 2014-12-30
    Interventions:
    • Drug: Ibrutinib Participants w
Recruiting Study Name: Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation
Condition: Haematological Malignancy
Date: 2017-05-07
Interventions: Drug: Nivolumab Injection Human monoclonal antibody targeting programmed death-1 (PD-1) cell surface rec
Next >>>